All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective ...

Researchers have mapped the genetic landscape of cancer drug resistance, uncovering that DNA changes can be grouped into four ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. | ...

Cambridge scientists and collaborators have mapped drug resistance across different cancers, highlighted DNA changes that may ...

Timothy Mullett, MD, leaned toward his computer screen as he spoke, drowning out the sounds of the busy coffee shop behind him to get his message across.

Panelists discuss how biomarker testing is currently utilized in the management of patients with small cell lung cancer (SCLC), including its timing within the treatment journey, while also exploring ...

SAN ANTONIO, October 18, 2024--bioAffinity Technologies announces pricing of $2.66 million registered direct offering and ...

BioAffinity Technologies shares declined after the company announced a $2.66 million registered direct offering of stock and a concurrent private placement of warrants. Shares were down 25%, to $1.59, ...

B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, provided an update today on the company's efforts to secure supplies of critical IV fluids in response to ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOYtm (zolbetuximab-clzb) in combination ...